AIkido Pharma, Inc. (NASDAQ: AIKI) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that applies artificial intelligence and machine learning to the discovery and development of novel small-molecule therapeutics. The company’s proprietary AI-driven platform integrates computational chemistry, structural biology and diverse biological data sets to identify and optimize drug candidates across immunology, oncology and fibrotic disease indications.
The company’s pipeline consists of several lead programs in preclinical and early clinical stages. AIK-201 is being evaluated for its potential to enhance anti-tumor immune responses by modulating key immuno-regulatory pathways. AIK-210 focuses on autoimmune and inflammatory disorders, leveraging targeted kinase inhibition to suppress aberrant immune activation. AIkido Pharma has also advanced a series of preclinical compounds aimed at fibrotic diseases, including kidney and pulmonary fibrosis, where high unmet medical need persists.
Founded in 2019 by a team of computational biologists and medicinal chemists, AIkido Pharma has rapidly expanded its research infrastructure with facilities in the United States and strategic collaborations with academic centers in Europe and Asia. The company completed its initial public offering in early 2023, securing capital to accelerate the development of its AI-designed small molecules and to broaden its partnerships across the biotech ecosystem.
Leadership at AIkido Pharma is headed by CEO David Wu, whose two decades of experience span roles in both large pharmaceutical companies and emerging biotech ventures. The executive team includes seasoned experts in drug discovery, translational science and regulatory affairs. Guided by a scientific advisory board composed of industry veterans and academic researchers, AIkido Pharma continues to advance its mission of bringing precision medicines from computational concept to clinical reality.
AI Generated. May Contain Errors.
